Cosmetics Regulation in Australia
Cosmetics and personal care products are regulated in different ways according to the country they are manufactured and made available. Regulatory compliance with international regulations is a critical factor for the internationalization of a cosmetic product. Since 1st July 2020, the Australian Industrial Chemicals Introduction Scheme (AICIS) is the entity responsible for controlling cosmetics. Cosmetic products must be used, advertised and presented in a specific way to be considered cosmetics rather than therapeutic goods.

COSMETICS VS THERAPEUTIC GOODS 

In Australia, beauty products are classified in two categories according to their use: cosmetics and therapeutic goods. The distinction between these two categories is not always clear and it can be made by a combination of factors: primary use or purpose of the product; the ingredients present and their effects on the body; how the product is applied and how the product is promoted, represented, presented or labelled.  

Australia’s Government defines cosmetic as a “substance that is designed to be used on any external part of the human body – or inside the mouth – to change its odours, change its appearance, cleanse it, keep it in good condition, perfume it or protect it”. 

Therapeutic good are “products that prevent, diagnose or treat diseases, or that affect the structure or functions of the human body”. The Therapeutic Goods Administration (TGA) is responsible for the management of the therapeutic goods. TGA only assesses cosmetic products that make therapeutic claims. 

The National Industrial Chemicals Notification and Assessment Scheme (NICNAS) was the former entity responsible for controlling cosmetics and soaps. Since 1st July 2020, NICNAS was replaced by a new scheme known as Australian Industrial Chemicals Introduction Scheme (AICIS). The product safety and cosmetic labelling standards are regulated by the Australian Competition and Consumer Commission (ACCC). All cosmetic products must be labelled in accordance with the mandatory standard for labelling cosmetic products (Trade Practices (Consumer Product Information Standards) (Cosmetics) Regulation 1991).  

COSMETICS REGULATION 

AICIS does not regulate therapeutic goods and it does not ban ingredients in products. AICIS may restrict the concentrations which companies can use and establish other conditions that companies need to follow. AICIS restricts the importation and manufacture of industrial chemicals by including conditions of use or secondary notification conditions on the chemicals it assesses. However, AICIS is not responsible for the following uses of chemicals. 

If a chemical is not for a therapeutic, agricultural, veterinary or food use, it is considered an industrial chemical. Nearly all cosmetic ingredients are regulated as industrial chemicals under the Industrial Chemicals Act 2019 (IC Act 2019 – new regulatory scheme), which is administered by AICIS. 

Manufacturers and importers of cosmetics or cosmetic ingredients must be registered with AICIS and all of the ingredients contained in a cosmetic must be listed on the Australian Inventory of Industrial Chemicals (AIIC) or notified to AICIS for pre-market assessment (unless an exemption applies). If an ingredient is not listed on the Inventory (AIIC) and notified to AICIS, it will be subject to public health, work health and safety (WHS), and environmental risk assessment.  

The AIIC lists more than 40 000 industrial chemicals that can be manufactured or imported into Australia and contains chemical identity information and regulatory obligations regarding that chemical.  

Importers and manufacturers introducing industrial chemicals for commercial purposes in this country must register their business and pay a fee (if not already registered with the former scheme – NICNAS) and categorize each chemical importation or manufacture into 1 of 5 categories. Importers and manufacturers have also the responsibility to submit declarations and reports, to keep records and provide information to AICIS when asked. 

Until 31st August 2022, there are categories of chemicals that are exempt from notification (according to former NICNAS exemptions). After this date, the company will need to categorize its introductions to ensure they comply with AICIS. The exemption categories are as follows:  

  • Research and development (less than 100 kg); 
  • Cosmetic use not exceeding 100 kg: 
  • Must pose no unreasonable risk to human health and the environment. 
  • Non-cosmetic use not exceeding 100 kg: 
  • Must pose no unreasonable risk to human health and the environment 
  • Cosmetic use at a concentration of less than 1%: 
  • Must be non-hazardous. 

Additionally, there is no need for notification if all ingredients (imported or manufactured) included in the product meet the definition of a “naturally-occurring chemical”. To legally meet this category, a “naturally-occurring chemical” must be one of the following: 

  • an unprocessed chemical that is found in nature (such as chemicals from plants, micro-organisms, animals, the earth and the sea); 
  • a chemical that is found in nature and extracted using a process that does not change its chemical composition. 

References: 

  1. Australian Government, Department of Health – Australian Industrial Chemicals Introduction Scheme (AICIS) – Overview of AICIS. Available at: https://www.industrialchemicals.gov.au/business/overview-aicis 
  1. Australian Government – Industrial Chemicals (Notification and Assessment) Act 1989 (ICNA Act) 
  1. Australian Government – Industrial Chemicals Act 2019 
  1. Australian Industrial Chemicals Introduction Scheme (AICIS) – Industrial Chemicals Categorisation Guidelines – Final Draft, 2019 

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »